Studying and understanding of tissue and disease mechanisms largely depend on the
availability of suitable and representative biological model systems. These model systems should …

Existing first-line cancer therapies often fail to cope with the heterogeneity and complexity of
cancers, so that new therapeutic approaches are urgently needed. Among novel alternative …

Drug–drug interactions (DDIs) occur when the pharmacological activity of one drug is
altered by a second drug. As multimorbidity and polypharmacotherapy are becoming more …

Microphysiological systems hold the promise to increase the predictive and translational
power of in vitro substance testing owing to their faithful recapitulation of human physiology. …

In vitro screening methods for compound efficacy and toxicity to date mostly include cell or
tissue exposure to preset constant compound concentrations over a defined testing period. …

Understanding the pharmacokinetic/pharmacodynamic (PK/PD)-relationship of a drug candidate
is key to determine effective, yet safe treatment regimens for patients. However, current …

Microfluidic-drop networks consist of several stable drops—interconnected through microfluidic
channels—in which organ models can be cultured long-term. Drop networks feature a …

Integrating flowing cells, such as immune cells or circulating tumour cells, within a
microphysiological system is crucial for body-on-a-chip applications. However, ensuring unimpeded …

The multifactorial nature of inflammatory bowel disease (IBD) necessitates reliable and practical
experimental models to elucidate its etiology and pathogenesis. To model the intestinal …

Despite increasing survival rates of pediatric leukemia patients over the past decades, the
outcome of some leukemia subtypes has remained dismal. Drug sensitivity and resistance …